Technically as trend reversal and breakout is due, page-16

Looking forward to seeing what operational cash flow will be for the last 6 months . With lower capex, higher margins and improved sales , lower returns and manufacturing of some product lines moving in house I would imagine cash flow of circa 60-70 m this half . I thus expect to see debt reduce.
I would like to see Mayne pharma do a small CR of 60-80 m if the SP recovers to over 1 dollar to beef of cash levels for some acquisitions at these times. Mayne continue to be a standout in terms of balance sheet optionality and increase revenue through acquisition without a comsumaerate increase in debt would be great.